Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene...

Full description

Bibliographic Details
Main Authors: Yanzhen Zhang, Huaigang Chen, Lang Hong, Hong Wang, Bin Li, Mengyin Zhang, Jiamei Li, Liu Yang, Fan Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
lipid-lowering therapies
cardiovascular risk
PCSK9
Inclisiran
siRNA
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1260921/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1260921/full

Similar Items